Carlyle Group CG is considering acquiring Baxter International's BAX kidney care spinoff, Vantive, in a deal valued at more than $4 billion, including debt. The news was first reported by Wall Street Journal, citing people familiar with the matter. Per the source, the companies started exclusive negotiations in late June and an agreement could be announced as soon as this week. However, there is a chance that the discussions will fail or another bidder may emerge. More than a year after announcing plans to separate the unit due to supply-chain issues and waning demand for dialysis operations, Baxter said in March that it has been in talks with selected private equity investors about the possibility of selling the kidney care unit. Baxter plans to spin off Vantive in the second half of 2024, intending to separate its acute therapies and renal care business. In 2023, Carlyle pulled back from investments in U.S. consumer brands. With the exit, CG's private equity business, U.S. strategy, focused on investments in health care, government services, industrials, technology and financial services. Markedly, Carlyle has been witnessing solid organic growth in the past several years on the back of strategic investments. The company is focusing on scaling its investment platforms, building out infrastructure credit and real estate credit and foraying into new avenues. These efforts are expected to support revenue growth. Our model estimates total revenues to witness a CAGR of 12.8% in the next three years ending 2026. Also, the company’s global presence and efforts to expand business are expected to continue aiding asset under management (AUM) growth and boost its investment performance. Carlyle would be making a big move if it were to acquire Vantive, since private equity deal-making is gradually picking up steam. Recently, Piper Sandler Companies PIPR announced a definitive agreement to buy Aviditi Advisors, an alternative investment bank. The acquisition will enhance the company’s capabilities in fundraising, secondary solutions and direct investment capital. Thus, it will further solidify PIPR’s leadership position in the private equity M&A and capital markets sectors. Shares of CG have gained 31.7% in the past year compared with the industry’s rise of 25.4%. Zacks Investment Research Image Source: Zacks Investment Research CG currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX):Free Stock Analysis Report Carlyle Group Inc. (CG):Free Stock Analysis Report Piper Sandler Companies (PIPR):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...